Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03296813 · ClinicalTrials.gov registry record · Phase 3
TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,973
- Enrollment target
NCT03296813: Completed Phase 3 study, sponsored by Duke University.
NCT03296813 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 2,973 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (285% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03296813, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,973 participants
- Enrollment target
Study Summary
TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over 12 months in patients with heart failure who are hospitalized.
Primary Outcome
Death information was obtained from the Call Center through 30 months for patients 1-500, through 24 months for patients 501-1000, through 18 months for patients 1001-1500, and through 12 months for the remaining patients (except those who were randomized \< 12 months when the study was stopped by the DSMB). Also death information was obtained through searches of the 2018-2021 National Death Index (NDI) database.
Interventions
- DRUG Furosemide
- DRUG Torsemide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,973 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 3 |
What the finished NCT03296813 record still lists
NCT03296813 is an interventional study that assigns participants to a tested intervention. Its 2,973 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (285% higher).
The record links to 0 conditions, and to 2 interventions - of which Furosemide is the first listed.
NCT03296813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03296813 about?
NCT03296813 is a clinical study titled "TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure". TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treat...
What is the current status of trial NCT03296813?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,973 participants. The study started on 2018-07-11. Estimated completion is 2022-07-29.
What interventions are being tested in trial NCT03296813?
The interventions under investigation include: Furosemide (DRUG), Torsemide (DRUG).
Who is sponsoring clinical trial NCT03296813?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03296813's enrollment target sits among peer trials
2,973 80th of 2000 higher than 1,921 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05297734 · 2,996 participants · NA
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- NCT03331380 · 2,950 participants · NA
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System
- NCT03860883 · 2,998 participants · NA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI